VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Vistagen Therapeutics, Inc. for alleged misrepresentations related to the company's Phase 3 PALISADE-3 trial of fasedienol, which is being developed for the treatment of social anxiety disorder [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased or acquired Vistagen's common stock between April 1, 2024, and December 16, 2025 [1]. - Defendants are accused of making false statements regarding the Phase 3 trial of fasedienol, an investigational drug [2]. Group 2: Lead Plaintiff Information - Interested parties wishing to serve as lead plaintiff must file papers by March 16, 2026 [3]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [3]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times [4].